Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

pembrolizumab 1280Specimen Handling 928Carboplatin 836Magnetic Resonance Spectroscopy 831Cyclophosphamide 807Cisplatin 735Nivolumab 679Paclitaxel 634Radiotherapy 617Gemcitabine 579Biopsy 560Bevacizumab 486Dexamethasone 444fludarabine 409Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 363Fluorouracil 358atezolizumab 353durvalumab 339Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 320Blood Specimen Collection 315Standard of Care 311Pemetrexed 308Ipilimumab 303Radiation 289

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carbamates × 1 year × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡